程序性细胞死亡蛋白-1(PD-1)抑制剂治疗晚期黑色素瘤合并原有自身免疫病或伊匹木单抗诱发自身免疫病的患者
这项回顾性研究纳入德国七家皮肤癌中心的41例晚期黑色素瘤患者,其中19例有原有自身免疫病(A组),22例有伊匹木单抗诱发的免疫相关不良事件(B组),评估PD-1抑制剂治疗期间原有自身免疫病复发和新发irAE及疗效。A组原有自身免疫病复发率为42%,新发irAE为16%;B组伊匹木单抗诱发irAE复发率为4.5%,新发irAE为23%。所有复发均经免疫抑制和/或对症治疗控制,未需终止PD-1抑制剂治疗;A组肿瘤缓解率32%,B组45%,与自身免疫发生无关。
要点
- A组原有自身免疫病复发率42%,新发irAE 16%;B组伊匹木单抗诱发irAE复发率4.5%,新发irAE 23%。
- 所有自身免疫病复发或irAE均经免疫抑制和/或对症治疗控制,未需终止PD-1抑制剂治疗。
- 肿瘤缓解率A组32%、B组45%,与自身免疫发生无关;作者认为PD-1抑制剂可考虑用于自身免疫病患者,取决于自身免疫病的严重程度和活动性。
核心结论
- 原有自身免疫病在PD-1抑制剂治疗期间常出现复发,而伊匹木单抗诱发的irAE复发罕见。
- 缓解率超过30%且与irAE无关;作者认为PD-1抑制剂可考虑用于自身免疫病患者,取决于自身免疫病的严重程度和活动性。
研究设计与样本
- 回顾性评估来自德国七家皮肤癌中心的晚期黑色素瘤患者,这些患者有原有自身免疫病或既往伊匹木单抗诱发的irAE并接受PD-1抑制剂治疗。
- 共41例患者:A组19例有原有自身免疫病(包括2例合并伊匹木单抗诱发的自身免疫性结肠炎),B组22例有伊匹木单抗诱发的irAE。
- 开始PD-1抑制剂治疗时,A组6例、B组2例需要免疫抑制治疗。
主要发现
- A组原有自身免疫病复发率为42%,新发irAE为16%。
- B组伊匹木单抗诱发irAE复发率为4.5%,新发irAE为23%。
- 所有原有自身免疫病复发或irAE均经免疫抑制和/或对症治疗控制,未需终止PD-1抑制剂治疗。
- 肿瘤缓解率A组为32%,B组为45%,与自身免疫发生无关。
临床怎么用
- 作者认为,PD-1抑制剂可考虑用于自身免疫病患者,取决于自身免疫病的严重程度和活动性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Programmed cell death protein 1 (PD-1) inhibitors are a common treatment strategy for metastatic melanoma and other tumour entities. Clinical trials usually exclude patients with preexisting autoimmune diseases, thus experience with PD-1 inhibitor (PD-1i) in this patient population is limited. PATIENTS AND METHODS: Metastatic melanoma patients with preexisting autoimmune disorders or previous ipilimumab-triggered immune-related adverse events (irAE) undergoing treatment with PD-1i from seven German skin cancer centres were evaluated retrospectively with regard to flare of the preexisting autoimmunity and development of new, not preexisting irAE as well as response to PD-1i therapy. RESULTS: In total, 41 patients had either preexisting autoimmunity (n=19, group A, including two patients with additional ipilimumab-triggered autoimmune colitis) or ipilimumab-triggered irAE (n=22, group B). At PD-1i therapy initiation, six patients in group A and two patients in group B required immunosuppressive therapy. In group A, a flare of preexisting autoimmune disorders was seen in 42% of patients, new irAE in 16%. In group B, 4.5% of patients showed a flare of ipilimumab-triggered irAE and 23% new irAE. All flares of preexisting autoimmune disorders or irAE were managed by immunosuppressive and/or symptomatic therapy and did not require termination of PD-1i therapy. tumour responses (32% in group A and 45% in group B) were unrelated to occurrence of autoimmunity. CONCLUSION: While preexisting autoimmunity commonly showed a flare during PD-1i therapy, a flare of ipilimumab-triggered irAE was rare. Response rates were above 30% and unrelated to irAE. PD-1i therapy can be considered in patients with autoimmune disorders depending on severity and activity of autoimmunity.
引用
- Gutzmer R, Koop A, Meier F, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017. PMID: 28214654. doi:10.1016/j.ejca.2016.12.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。